Trial reportEuropean journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery2025
Editor's Choice - Bypass After Failed Endovascular Intervention Is Associated with an Increased Risk of Above Ankle Amputation Among Patients with Chronic Limb Threatening Ischaemia in a Randomised Trial Population.
Trial report in European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveOne concern about the endovascular first (ENDO) approach for chronic limb threatening ischaemia (CLTI) is whether bridges are burned for a secondary bypass (SB) if required in the future. This secondary analysis of a prospective randomised trial aimed to compare above ankle amputation rates in patients with CLTI treated with primary bypass (PB) compared with those treated with SB after an initial ENDO approach.
methodsData from the randomised unblinded Best Endovascular versus Best Surgical Therapy of Patients with CLTI (BEST-CLI) trial were analysed. Patients were included if they had CLTI and were considered as candidates for open or ENDO revascularisation with the primary outcomes being major adverse limb free event survival. There were two parallel cohorts based on whether single segment great saphenous vein (SSGSV) was (cohort 1) or was not (cohort 2) available. Primary bypass was compared with SB after index ENDO using the primary outcome of above ankle amputation with death as a competing risk. Multivariable and propensity matched analyses were performed.
resultsThere were 665 PB and 158 SB in cohort 1 and 192 PB and 45 SB in cohort 2. Time to SB after ENDO occurred at a median of 28 days in all patients and at a median of 210 days in those who had a successful initial ENDO procedure. Unadjusted one year analysis showed SB to be associated with increased above ankle amputation (14% vs. 8.1%; p = .002) overall. Secondary bypass was associated with increased above ankle amputation in cohort 1 (13.5% vs. 7.4%; p = .003), whereas this was not statistically significant in cohort 2 (15.9% vs. 10.9%; p = .28). These findings were confirmed on multivariable analysis (adjusting for age, sex, wound ischaemia foot infection stage, randomisation strata, diabetes mellitus, end stage kidney disease, previous index infrainguinal reconstruction, and smoking history) for cohort 1, with SB associated with increased above ankle amputation (HR 1.72, 95% CI 1.08 - 2.73; p = .020), remaining true when restricting to SB after a technically successful ENDO (HR 2.21, 95% CI 1.26 - 3.86; p =.005). Results were similar on propensity matched analyses.
conclusionIn patients with CLTI deemed suitable for either open or ENDO, SB was associated with worse limb salvage compared with PB, particularly in patients with an available SSGSV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.